MXN tablets
Dexa Medica
Ingredients in every tablet
Moxifloxacin | 400 mg |
Each package contains
Other details
Flavour | None |
W.H.O. classification
ATC Level 1 | J - Antiinfectives for systemic use |
ATC Level 2 | J01 - Antibacterials for Systemic Use |
ATC Level 3 | J01M - Quinolone Antibacterials |
Warnings
Pregnancy
Lactation
Alcohol
Machinery
Available in
![]() |
Indonesia |
Dosage information
18 YEARS OLD AND ABOVE
The recommended dose for moxifloxacin is one 400 mg tablet once daily. No adjustment of dosage is required in elderly patients.
For treatment of skin and soft tissue infections requiring initial intravenous therapy followed by administration of 400 mg moxifloxacin tablet.
The film-coated tablets should be swallowed whole with sufficient liquid and may be taken independent of meals.
Duration of treatment
Moxifloxacin tablet should be used for the following treatment durations:
- Acute exacerbation of chronic bronchitis for 5-10 days.
- Community-acquired pneumonia for 10 days.
- Acute sinusitis for 7 days.
- Complicated skin and soft tissue for 7-21 days.
The recommended dose (400 mg once daily) and duration of therapy for the indication being treated should not be exceeded
0 TO 18 YEARS OLD
Efficacy and safety have not been established.
The film-coated tablets should be swallowed whole with sufficient liquid and may be taken independent of meals.
Duration of treatment
Moxifloxacin tablet should be used for the following treatment durations:
- Acute exacerbation of chronic bronchitis for 5-10 days.
- Community-acquired pneumonia for 10 days.
- Acute sinusitis for 7 days.
- Complicated skin and soft tissue for 7-21 days.
The recommended dose (400 mg once daily) and duration of therapy for the indication being treated should not be exceeded
IMPAIRED LIVER FUNCTION
No dosage adjustment is required in patients with impaired liver function (creatinine clearance ≤30 ml/minute/1.73m²).
Indication
Moxifloxacin is indicated for the treatment in Adults (> 18 years of age) for the following bacterial infections:
a. Upper respiratory tract infections
– Acute exacerbations of chronic bronchitis.
– Community-acquired pneumonia
– Acute sinusitis.
b. Skin and soft tissue infections
Moxifloxacin is indicated for the treatment of the infections caused by bacteria susceptible to moxifloxacin.